Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
| Revenue (TTM) | $26.30B |
| Gross Profit (TTM) | $17.28B |
| EBITDA | $7.51B |
| Operating Margin | 23.00% |
| Return on Equity | 16.00% |
| Return on Assets | 8.36% |
| Revenue/Share (TTM) | $68.70 |
| Book Value | $61.62 |
| Price-to-Book | 5.44 |
| Price-to-Sales (TTM) | 4.72 |
| EV/Revenue | 5.29 |
| EV/EBITDA | 20.15 |
| Quarterly Earnings Growth (YoY) | -11.70% |
| Quarterly Revenue Growth (YoY) | 7.60% |
| Shares Outstanding | $380.69M |
| Float | $345.26M |
| % Insiders | 5.41% |
| % Institutions | 84.05% |
Volatility is currently expanding
The Fund returned 3.18% compared to a 2.61% return for the Russell 1000 Value Index. Key contributors include Microsoft, Salesforce and Thermo Fisher Scientific. Key detractors include Aon, Carrier Global and Builders FirstSource.
Stryker shares plunge 11.8% after Q3 earnings and sales miss estimates, prompting a 2026 outlook cut amid weak joint procedures and execution challenges.
SAN FRANCISCO, Oct. 30, 2026 /PRNewswire/ -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists. The move lower wiped out over $10 billion of Stryker's market capitalization.
Stryker cuts its 2026 outlook amid weaker joint replacement demand and supply disruptions, despite MedSurg strength, margin gains and robotics investments.
Stryker NYSE: SYK reported third-quarter organic sales growth of 7.7% and adjusted earnings per share of $3.52, while lowering its full-year outlook to reflect a slowdown in hip and knee procedures, lingering peripheral vascular supply constraints and execution risks tied to capital equipment sales.
Medical device maker Stryker (NYSE:SYK | SYK Price Prediction) shares fell about 10% before the open Friday to $279.98, compared with Thursday's close of $311.75. The quarter missed expectations on both lines.
Stryker Corporation (SYK) Q3 2026 Earnings Call Transcript
Portage, Michigan, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2026:
SYK's Q3 earnings may reflect strong hospital equipment demand and cybersecurity recovery, but supply constraints, vascular disruptions and margin pressures remain.
Portage, Michigan, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Jefferies Global Healthcare Conference on Tuesday, November 17, 2026, at the Waldorf Hilton and ME Hotel in London. Spencer Stiles, President, Chief Operating Officer, Preston Wells, Vice President, Chief Financial Officer and Nick Mead, Vice President, Investor Relations will also participate in a fireside chat session at 8:30 a.m.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SYK and any ticker you trade — then tracks every position and per-strategy win rate.
